Buy REVANESSE® SHAPE+™ with Lidocaine Online

The REVANESSE® SHAPE+ product is a cross-linked hyaluronic acid filler used for cosmetic and reconstructive purposes, primarily focusing on correcting medium to deep facial rhytides (wrinkles) and lipoatrophy (volume loss). This injectable filler helps to restore lost facial volume and improve facial contours. It is particularly indicated for the treatment of HIV-associated lipoatrophy, lipodystrophy, and various soft tissue deformities caused by trauma or other pathological conditions.

REVANESSE® SHAPE+ Indications for Use

REVANESSE® SHAPE+ is intended for patients seeking to correct facial contour deficiencies, restore volume, and treat medium to deep facial wrinkles. The filler is also suitable for lip augmentation, skin hydration, and the correction of anatomical deformities or soft tissue loss. Cosmetic indications primarily include facial rhytides and volume restoration.

REVANESSE® SHAPE+ Dosage Information

The product comes in two 1.2 mL pre-filled syringes, with each syringe containing 25 mg/mL of cross-linked hyaluronic acid and 0.3% w/w of lidocaine to reduce discomfort during injection. The dosage should be determined by the medical professional based on the area treated and the patient’s needs. The product should be injected slowly, with minimal pressure to achieve optimal results. The typical duration of the product’s effect is between 6 to 12 months, depending on the depth and location of the injection.

REVANESSE® SHAPE+ Side Effects and Precautions

As with all injectable treatments, there are potential side effects and risks associated with the use of REVANESSE® SHAPE+. Common injection-related reactions include erythema (redness), swelling, pain, itching, discoloration, and tenderness at the injection site. These reactions are typically mild and resolve within one week. Nodules or induration at the injection site can also occur.

In rare cases, more serious complications such as glabellar necrosis, abscess formation, granulomas, and hypersensitivity reactions have been reported. These reactions can develop shortly after the injection or be delayed by 2 to 4 weeks. Though hypersensitivity reactions are rare (less than 1 in 1500 treatments), prolonged erythema, swelling, and induration have been observed in some cases.

It is critical to avoid injecting the product into blood vessels as this could lead to vascular occlusion, ischemia, or embolism. The filler should not be used in areas with permanent implants, or in conjunction with other fillers, lasers, or skin resurfacing treatments such as chemical peels or dermabrasion. Additionally, patients with hypertrophic scarring, active skin inflammation, autoimmune disorders, or multiple allergies should not be treated with REVANESSE® SHAPE+.

REVANESSE® SHAPE+ Clinical Studies or Real-World Outcomes

Clinical outcomes of REVANESSE® SHAPE+ injections typically show an improvement in facial volume and contour, with a noticeable reduction in the severity of facial wrinkles and lines. Patients often report high levels of satisfaction with the treatment’s ability to enhance facial aesthetics and achieve a natural-looking result. The longevity of the product varies from patient to patient but generally lasts between 6 to 12 months.

REVANESSE® SHAPE+ Drug Interactions

REVANESSE® SHAPE+ contains lidocaine, which could interact with other local anesthetics or antiarrhythmic medications such as mexiletine or tocainide, potentially causing systemic toxicity. Additionally, patients on anticoagulants or medications that increase bleeding risk (e.g., aspirin, NSAIDs, St. John’s Wort, or high doses of Vitamin E) should be informed about the potential for increased bruising and bleeding at the injection site.

REVANESSE® SHAPE+ Administration Technique

Only trained healthcare professionals should administer REVANESSE® SHAPE+. Proper injection techniques are crucial to the success of the treatment. The injection should be made slowly, and the product should be applied under sterile conditions. Before the injection, it is important to ensure that the product is stored at room temperature for at least 30 minutes and to inspect the product for any signs of damage or contamination. The injection technique must be precise, especially when working near delicate or highly vascular areas like the glabella and nose region. Injectors should avoid excessive pressure and should immediately stop the procedure if there are signs of skin blanching, changes in vision, or any other indication of vascular complications.

REVANESSE® SHAPE+ Precautions

Healthcare providers should take several precautions before and after administering REVANESSE® SHAPE+. Patients should avoid touching the treated area for 12 hours after the injection and should refrain from prolonged exposure to sunlight, UV rays, or extreme temperatures until swelling and redness subside. In cases of previous cold sore outbreaks, there is a risk of triggering new outbreaks at the injection site.

The product is not recommended for patients under 18 or over 65 years of age, and it should not be administered to visibly ill patients or those with viral or bacterial infections. Health practitioners are encouraged to fully inform patients of the risks, and patients should be educated on the signs of complications.